</ iframe></noscript> <!-- End Google Tag Manager (noscript) --> <div id="page" class="site"><a aria-label="skip to content" class="skip-link" href="#content">Skip to Content</a> <header class="site-header header-layout-three header-layout-seven header-layout-eight" itemscope itemtype="http://schema.org/WPHeader"> <div class="header-holder"> <div class="header-m" style="background-image:url(https://ddblog.labcorp.com/wp-content/uploads/2021/07/blog-header-1.png)"> <div class="container"> <div class="site-branding" itemscope itemtype="http://schema.org/Organization"> <p class="site-title" itemprop="name"><a href="https://ddblog.labcorp.com/" rel="home" itemprop="url">Insights From Our Labs to Yours</a></p> <p class="site-description" itemprop="description">Labcorp Blog</p> </div> </div> </div> </div> <div class="sticky-holder"></div> <div class="header-b"> <div class="container"> <button aria-label="primary menu toggle" id="primary-toggle-button"><i class="fa fa-bars"></i>Navigation</button> <nav id="site-navigation" class="main-navigation" itemscope itemtype="http://schema.org/SiteNavigationElement"> <div class="menu-main-container"><ul id="primary-menu" class="menu"><li id="menu-item-6077" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-6077"><a href="https://ddblog.labcorp.com">Home</a></li> <li id="menu-item-5821" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-has-children menu-item-5821"><a href="https://ddblog.labcorp.com/industry/">Industry</a> <ul class="sub-menu"> <li id="menu-item-5824" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5824"><a href="https://ddblog.labcorp.com/industry/device/">Device</a></li> <li id="menu-item-5825" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5825"><a href="https://ddblog.labcorp.com/industry/drug-development/">Drug</a></li> <li id="menu-item-5822" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5822"><a href="https://ddblog.labcorp.com/industry/chemical/">Chemical</a></li> <li id="menu-item-5823" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5823"><a href="https://ddblog.labcorp.com/industry/crop/">Crop</a></li> </ul> </li> <li id="menu-item-5828" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-has-children menu-item-5828"><a href="https://ddblog.labcorp.com/phase/">Phase</a> <ul class="sub-menu"> <li id="menu-item-5829" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5829"><a href="https://ddblog.labcorp.com/phase/discovery/">Discovery</a></li> <li id="menu-item-5835" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5835"><a href="https://ddblog.labcorp.com/phase/preclinical-nonclinical/">Preclinical/Nonclinical</a></li> <li id="menu-item-5831" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5831"><a href="https://ddblog.labcorp.com/phase/phase-i-iia/">Phase I-IIa</a></li> <li id="menu-item-5832" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5832"><a href="https://ddblog.labcorp.com/phase/phase-iib-iii/">Phase IIb-III</a></li> <li id="menu-item-5833" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5833"><a href="https://ddblog.labcorp.com/phase/pilot/">Pilot</a></li> <li id="menu-item-5834" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5834"><a href="https://ddblog.labcorp.com/phase/pivotal/">Pivotal</a></li> <li id="menu-item-5830" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5830"><a href="https://ddblog.labcorp.com/phase/formulation-packaging/">Formulation, Packaging, etc.</a></li> </ul> </li> <li id="menu-item-5836" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-has-children menu-item-5836"><a href="https://ddblog.labcorp.com/molecule-type/">Molecule Type</a> <ul class="sub-menu"> <li id="menu-item-5837" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5837"><a href="https://ddblog.labcorp.com/molecule-type/biologics/">Biologics</a></li> <li id="menu-item-5841" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5841"><a href="https://ddblog.labcorp.com/molecule-type/small-molecules/">Small Molecules</a></li> <li id="menu-item-5839" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5839"><a href="https://ddblog.labcorp.com/molecule-type/biosimilars/">Biosimilars</a></li> <li id="menu-item-5838" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5838"><a href="https://ddblog.labcorp.com/molecule-type/biomarkers/">Biomarkers</a></li> <li id="menu-item-5840" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5840"><a href="https://ddblog.labcorp.com/molecule-type/cell-gene-therapies/">Cell/Gene Therapies</a></li> </ul> </li> <li id="menu-item-5844" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-has-children menu-item-5844"><a href="https://ddblog.labcorp.com/data-informatics/">Data/Informatics</a> <ul class="sub-menu"> <li id="menu-item-5842" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5842"><a href="https://ddblog.labcorp.com/data-informatics/send/">SEND</a></li> <li id="menu-item-5845" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5845"><a href="https://ddblog.labcorp.com/data-informatics/modeling/">Modeling</a></li> <li id="menu-item-5846" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5846"><a href="https://ddblog.labcorp.com/data-informatics/patient-recruitment/">Patient Recruitment</a></li> <li id="menu-item-5843" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5843"><a href="https://ddblog.labcorp.com/data-informatics/xcellerate/">Xcellerate</a></li> </ul> </li> <li id="menu-item-5827" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-has-children menu-item-5827"><a href="https://ddblog.labcorp.com/about-covance/">About Us</a> <ul class="sub-menu"> <li id="menu-item-5704" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-5704"><a href="https://ddblog.labcorp.com/about-covance/careers-and-culture/">Careers and Culture</a></li> <li id="menu-item-5792" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5792"><a href="http://response.covance.com/contact-us?elqCampaignId=399&cid=Web_Clk_CVD_blog_megamenunav_0615_399">Contact Us</a></li> <li id="menu-item-5791" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5791"><a href="https://drugdevelopment.labcorp.com">Labcorp Drug Development</a></li> </ul> </li> </ul></div> </nav><!-- #site-navigation --> <div class="right"> <div class="tools"> <div class="form-section"> <button aria-label="search form toggle" id="btn-search"><i class="fa fa-search"></i></button> <div class="form-holder"> <form role="search" method="get" class="search-form" action="https://ddblog.labcorp.com/"> <label> <span class="screen-reader-text">Search for:</span> <input type="search" class="search-field" placeholder="Search …" value="" name="s" /> </label> <input type="submit" class="search-submit" value="Search" /> </form> </div> </div> </div> <ul class="social-networks"> <li><a href="https://www.linkedin.com/company/labcorpdrugdevelopment" target="_blank" rel="nofollow"><i class="fab fa-linkedin"></i></a></li> <li><a href="https://twitter.com/LabcorpDrugDev" target="_blank" rel="nofollow"><i class="fab fa-twitter-square"></i></a></li> <li><a href="https://www.facebook.com/LabcorpDrugDevelopment" target="_blank" rel="nofollow"><i class="fab fa-facebook"></i></a></li> </ul> </div> </div> </div> </header> <div class="top-bar"> <div class="container"> <header class="page-header"> <h1 class="page-title">Oncology</h1> </header><!-- .page-header --> <div class="breadcrumb-wrapper"> <div id="crumbs" itemscope itemtype="http://schema.org/BreadcrumbList"> <span itemprop="itemListElement" itemscope itemtype="http://schema.org/ListItem"> <a itemprop="item" href="https://ddblog.labcorp.com"><span itemprop="name">Home</span></a> <meta itemprop="position" content="1" /> <span class="separator">/</span> </span> <span itemprop="itemListElement" itemscope itemtype="http://schema.org/ListItem"><a itemprop="item" href="https://ddblog.labcorp.com/therapeutic-area/"><span itemprop="name">Therapeutic Area </span></a><meta itemprop="position" content="2" /><span class="separator">/</span></span> <span class="current" itemprop="itemListElement" itemscope itemtype="http://schema.org/ListItem"> <a itemprop="item" href="https://ddblog.labcorp.com/therapeutic-area/oncology/"><span itemprop="name">Oncology</span></a><meta itemprop="position" content="3" /> </span></div></div><!-- .breadcrumb-wrapper --> </div> </div> <div class="container main-content"> <div id="content" class="site-content"> <div class="row"> <div id="primary" class="content-area"> <main id="main" class="site-main"> <div class="row"> <article id="post-9104" class="post-9104 post type-post status-publish format-standard has-post-thumbnail hentry category-clinical-development category-central-laboratory-services category-drug-development category-oncology category-phase-i-iia category-phase-iib-iii tag-clinical-trials tag-immuno-oncology-2 tag-oncology latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1-450x300.jpg" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Shot of a smiling senior doctor with a digital tablet talking to a female patient at hospital. Medical professional discussing with woman at nursing home." srcset="https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1-450x300.jpg 450w, https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1-300x200.jpg 300w, https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1-90x60.jpg 90w, https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1.jpg 600w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="9105" data-permalink="https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/doctor-discussing-with-woman-at-nursing-home-2/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1.jpg" data-orig-size="600,400" data-comments-opened="0" data-image-meta="{"aperture":"1.4","credit":"Getty Images","camera":"Canon EOS 5D Mark IV","caption":"Shot of a smiling senior doctor with a digital tablet talking to a female patient at hospital. Medical professional discussing with woman at nursing home.","created_timestamp":"1557240274","copyright":"","focal_length":"35","iso":"100","shutter_speed":"0.001","title":"Doctor discussing with woman at nursing home","orientation":"1"}" data-image-title="Doctor discussing with woman at nursing home" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1-300x200.jpg" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2023/01/GettyImages-1204666788-600x400-bf06395-1.jpg" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/&title=4%20emerging%20trends%20to%20watch%20in%20immunotherapy%20clinical%20trials" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=4%20emerging%20trends%20to%20watch%20in%20immunotherapy%20clinical%20trials https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#112e4264737b7472652c25342321747c746376787f763423216563747f7562342321657e3423216670657279342321787f342321787c7c647f7e65797463706168342321727d787f7872707d342321656378707d6237322122292a537e75682c79656561622b3e3e7575737d7e763f7d7073727e63613f727e7c3e232123223e21203e253c747c746376787f763c6563747f75623c657e3c66706572793c787f3c787c7c647f7e657974637061683c727d787f7872707d3c656378707d623e" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/" rel="bookmark">4 emerging trends to watch in immunotherapy clinical trials</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2023/01/4-emerging-trends-to-watch-in-immunotherapy-clinical-trials/" rel="bookmark"><time class="entry-date published updated" datetime="2023-04-17T16:25:49-04:00" itemprop="dateModified">Monday, April 17, 2023</time><time class="updated" datetime="2023-01-17T15:32:42-05:00" itemprop="datePublished">Tuesday, January 17, 2023</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-9104 --> <article id="post-9052" class="post-9052 post type-post status-publish format-standard has-post-thumbnail hentry category-clinical-development category-oncology category-phase-i-iia tag-long-term-follow-up-2 tag-long-term-follow-up-study tag-long-term-follow-up-clinical-trials tag-patient-centricity tag-patient-centricity-in-clinical-trials latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400-450x300.png" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Three generation family looking at old photographs, laughing" srcset="https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400-450x300.png 450w, https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400-300x200.png 300w, https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400-90x60.png 90w, https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400.png 600w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="9053" data-permalink="https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/600x400/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400.png" data-orig-size="600,400" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="600×400" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400-300x200.png" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2022/11/600x400.png" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/&title=How%20patient-centricity%20embeds%20value%20and%20stability%20in%20LTFU%20studies" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=How%20patient-centricity%20embeds%20value%20and%20stability%20in%20LTFU%20studies https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#c7f894b2a5ada2a4b3fa8fa8b0e2f5f7b7a6b3aea2a9b3eaa4a2a9b3b5aea4aeb3bee2f5f7a2aaa5a2a3b4e2f5f7b1a6abb2a2e2f5f7a6a9a3e2f5f7b4b3a6a5aeabaeb3bee2f5f7aea9e2f5f78b938192e2f5f7b4b3b2a3aea2b4e1e4f7f4fffc85a8a3befaafb3b3b7b4fde8e8a3a3a5aba8a0e9aba6a5a4a8b5b7e9a4a8aae8f5f7f5f5e8f6f6e8afa8b0eab7a6b3aea2a9b3eaa4a2a9b3b5aea4aeb3beeaa2aaa5a2a3b4eab1a6abb2a2eaa6a9a3eab4b3a6a5aeabaeb3beeaaea9eaabb3a1b2eab4b3b2a3aea2b4e8" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/" rel="bookmark">How patient-centricity embeds value and stability in LTFU studies</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2022/11/how-patient-centricity-embeds-value-and-stability-in-ltfu-studies/" rel="bookmark"><time class="entry-date published updated" datetime="2022-11-16T18:00:09-05:00" itemprop="dateModified">Wednesday, November 16, 2022</time><time class="updated" datetime="2022-11-16T18:00:08-05:00" itemprop="datePublished">Wednesday, November 16, 2022</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-9052 --> <article id="post-9038" class="post-9038 post type-post status-publish format-standard has-post-thumbnail hentry category-cell-gene-therapies category-oncology category-phase-i-iia category-phase-iib-iii tag-adc-antibody tag-antibody-drug-conjugates tag-immune-checkpoint-inhibitors tag-metastatic-breast-cancer tag-metastatic-breast-cancer-drugs tag-metastatic-breast-cancer-immunotherapies tag-metastatic-breast-cancer-indications tag-metastatic-breast-cancer-therapy tag-metastatic-breast-cancer-treatment latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395-450x300.jpg" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Mature woman with cancer standing with doctor at hospital" srcset="https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395-450x300.jpg 450w, https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395-300x200.jpg 300w, https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395-90x60.jpg 90w, https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395.jpg 600w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="9039" data-permalink="https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/mature-woman-standing-with-doctor-at-hospital/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395.jpg" data-orig-size="600,400" data-comments-opened="0" data-image-meta="{"aperture":"2.8","credit":"Getty Images\/Cavan Images RF","camera":"Canon EOS 5D Mark II","caption":"USA, Ohio, Cincinnati","created_timestamp":"1304414377","copyright":"\u00a9Jonathan Chapman","focal_length":"70","iso":"160","shutter_speed":"0.02","title":"Mature woman standing with doctor at hospital","orientation":"1"}" data-image-title="Mature woman standing with doctor at hospital" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395-300x200.jpg" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2022/10/GettyImages-961210118-600x400-bf06395.jpg" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/&title=Exploring%20metastatic%20breast%20cancer%20immunotherapies:%20Are%20ADCs%20and%20ICIs%20the%20answer?" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Exploring%20metastatic%20breast%20cancer%20immunotherapies:%20Are%20ADCs%20and%20ICIs%20the%20answer? https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#0c335f796e66696f783149747c60637e65626b293e3c6169786d7f786d78656f293e3c6e7e696d7f78293e3c6f6d626f697e293e3c6561617962637864697e6d7c65697f36293e3c4d7e69293e3c4d484f7f293e3c6d6268293e3c454f457f293e3c786469293e3c6d627f7b697e332a2f3c3f34374e636875316478787c7f36232368686e60636b22606d6e6f637e7c226f6361233e3c3e3e233d3c2369747c60637e65626b216169786d7f786d78656f216e7e696d7f78216f6d626f697e216561617962637864697e6d7c65697f216d7e69216d686f7f216d626821656f657f21786469216d627f7b697e23" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/" rel="bookmark">Exploring metastatic breast cancer immunotherapies: Are ADCs and ICIs the answer?</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2022/10/exploring-metastatic-breast-cancer-immunotherapies-are-adcs-and-icis-the-answer/" rel="bookmark"><time class="entry-date published updated" datetime="2022-10-17T14:41:54-04:00" itemprop="dateModified">Monday, October 17, 2022</time><time class="updated" datetime="2022-10-17T14:41:53-04:00" itemprop="datePublished">Monday, October 17, 2022</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Breast cancer is the most common malignancy in women and the second most common cancer worldwide.1 Rates of breast cancer are increasing in many parts of the world, reflecting its association with social and lifestyle factors related to economic development, as well as increases in life expectancy.2 Although the disease … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-9038 --> <article id="post-9002" class="post-9002 post type-post status-publish format-standard has-post-thumbnail hentry category-cell-gene-therapies category-oncology category-preclinical-nonclinical tag-cell-gene-therapy tag-cmc tag-ddpcr tag-oncology tag-preclinical-oncology tag-rare-diseases latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt-450x300.png" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Two scientists working together in a lab" srcset="https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt-450x300.png 450w, https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt-300x200.png 300w, https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt-90x60.png 90w, https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt.png 600w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="9003" data-permalink="https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/blogcgt/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt.png" data-orig-size="600,400" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="blogcgt" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt-300x200.png" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2022/08/blogcgt.png" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/&title=Cell%20and%20Gene%20Therapy%20Answers:%20Bioanalytical%20support%20for%20cell%20and%20gene%20therapy" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Cell%20and%20Gene%20Therapy%20Answers:%20Bioanalytical%20support%20for%20cell%20and%20gene%20therapy https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#4d721e382f27282e39700e282121687f7d2c2329687f7d0a282328687f7d1925283f2c3d34687f7d0c233e3a283f3e77687f7d0f24222c232c213439242e2c21687f7d3e383d3d223f39687f7d2b223f687f7d2e282121687f7d2c2329687f7d2a282328687f7d3925283f2c3d346b6e7d7e75760f222934702539393d3e77626229292f21222a63212c2f2e223f3d632e2220627f7d7f7f627d75622e282121602c2329602a282328603925283f2c3d34602c233e3a283f3e602f24222c232c213439242e2c21603e383d3d223f39602b223f602e282121602c2329602a282328603925283f2c3d3462" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/" rel="bookmark">Cell and Gene Therapy Answers: Bioanalytical support for cell and gene therapy</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2022/08/cell-and-gene-therapy-answers-bioanalytical-support-for-cell-and-gene-therapy/" rel="bookmark"><time class="entry-date published updated" datetime="2023-08-31T12:08:44-04:00" itemprop="dateModified">Thursday, August 31, 2023</time><time class="updated" datetime="2022-08-15T11:47:12-04:00" itemprop="datePublished">Monday, August 15, 2022</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Your source for answers to the complex challenges of cell and gene therapy development. We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp drug development, regarding bioanalytical support for cell and gene therapy modalities. He shared some of the current challenges in cell and gene therapy, … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-9002 --> <article id="post-8713" class="post-8713 post type-post status-publish format-standard has-post-thumbnail hentry category-drug-development category-oncology category-phase-i-iia category-phase-iib-iii category-preclinical-nonclinical tag-flow-cytometry tag-hematological-malignancies tag-measurable-residual-disease-mrd tag-mrd-testing latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1-450x300.png" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Cancer Cells" srcset="https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1-450x300.png 450w, https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1-300x200.png 300w, https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1-90x60.png 90w, https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1.png 600w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="8716" data-permalink="https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/cells-2/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1.png" data-orig-size="600,400" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cells" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1-300x200.png" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2022/02/cells-1.png" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/&title=Detecting%20measurable%20residual%20disease%20(MRD)%20in%20hematological%20malignancies%20using%20flow%20cytometry" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Detecting%20measurable%20residual%20disease%20(MRD)%20in%20hematological%20malignancies%20using%20flow%20cytometry https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#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" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/" rel="bookmark">Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/sme/">Labcorp's SME</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2022/03/detecting-measurable-residual-disease-mrd-in-hematological-malignancies-using-flow-cytometry/" rel="bookmark"><time class="entry-date published updated" datetime="2022-03-04T09:31:09-05:00" itemprop="dateModified">Friday, March 4, 2022</time><time class="updated" datetime="2022-03-04T09:31:08-05:00" itemprop="datePublished">Friday, March 4, 2022</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-8713 --> <article id="post-8603" class="post-8603 post type-post status-publish format-standard has-post-thumbnail hentry category-clinical-development category-drug-development category-oncology category-phase-i-iia category-phase-iib-iii tag-allogeneic tag-autologous tag-cell-therapies tag-gene-therapies tag-oncology tag-patient-access tag-recruitment latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2021/12/CGT-Answers-450x300.png" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Patient talking to doctor" data-attachment-id="8608" data-permalink="https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/cgt-answers/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/CGT-Answers.png" data-orig-size="640,360" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="CGT Answers" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/CGT-Answers-300x169.png" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/CGT-Answers.png" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/&title=Cell%20&%20Gene%20Therapy%20Answers:%20Addressing%20Challenges%20and%20De-risking%20Clinical%20Oncology%20Development" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Cell%20&%20Gene%20Therapy%20Answers:%20Addressing%20Challenges%20and%20De-risking%20Clinical%20Oncology%20Development https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#8bb4d8fee9e1eee8ffb6c8eee7e7aeb9bbada8bbb8b3b0aeb9bbcceee5eeaeb9bbdfe3eef9eafbf2aeb9bbcae5f8fceef9f8b1aeb9bbcaefeff9eef8f8e2e5ecaeb9bbc8e3eae7e7eee5eceef8aeb9bbeae5efaeb9bbcfeea6f9e2f8e0e2e5ecaeb9bbc8e7e2e5e2e8eae7aeb9bbc4e5e8e4e7e4ecf2aeb9bbcfeefdeee7e4fbe6eee5ffada8bbb8b3b0c9e4eff2b6e3fffffbf8b1a4a4efefe9e7e4eca5e7eae9e8e4f9fba5e8e4e6a4b9bbb9baa4bab9a4e8eee7e7a6eceee5eea6ffe3eef9eafbf2a6eae5f8fceef9f8a6eaefeff9eef8f8e2e5eca6e8e3eae7e7eee5eceef8a6eae5efa6efeea6f9e2f8e0e2e5eca6efeefdeee7e4fbe6eee5ffa4" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/" rel="bookmark">Cell & Gene Therapy Answers: Addressing Challenges and De-risking Clinical Oncology Development</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2021/12/cell-gene-therapy-answers-addressing-challenges-and-de-risking-development/" rel="bookmark"><time class="entry-date published updated" datetime="2023-09-13T15:39:10-04:00" itemprop="dateModified">Wednesday, September 13, 2023</time><time class="updated" datetime="2021-12-08T09:17:59-05:00" itemprop="datePublished">Wednesday, December 8, 2021</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Our Labcorp Cell & Gene Therapy team shared some of the advantages and challenges of cell & gene therapy, key differences between autologous and allogeneic cell therapies and how to overcome common hurdles to enable effective patient access, recruitment and retention to advance these novel therapeutics. We recently spoke with … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-8603 --> <article id="post-8596" class="post-8596 post type-post status-publish format-standard has-post-thumbnail hentry category-clinical-development category-drug-development category-oncology category-phase-iib-iii tag-oncology tag-patient-centricity latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2021/12/GettyImages-1175131240-450x300.png" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Doctor with Oncology Patient" data-attachment-id="8598" data-permalink="https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/gettyimages-1175131240/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/GettyImages-1175131240.png" data-orig-size="640,360" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="GettyImages 1175131240" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/GettyImages-1175131240-300x169.png" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2021/12/GettyImages-1175131240.png" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/&title=Technologies,%20tools%20and%20processes%20to%20support%20patient-centric%20oncology%20trials" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Technologies,%20tools%20and%20processes%20to%20support%20patient-centric%20oncology%20trials https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#57680422353d3234236a0332343f39383b38303e32247b7265672338383b247265673639337265672725383432242432247265672338726567242227273825237265672736233e3239237a34323923253e34726567383934383b38302e72656723253e363b24717467646f6c1538332e6a3f232327246d78783333353b3830793b3635343825277934383a7865676566786665782332343f39383b38303e32247a2338383b247a3639337a2725383432242432247a23387a242227273825237a2736233e3239237a34323923253e347a383934383b38302e7a23253e363b2478" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/" rel="bookmark">Technologies, tools and processes to support patient-centric oncology trials</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/oncology/">Labcorp Oncology</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2021/12/technologies-tools-and-processes-to-support-patient-centric-oncology-trials/" rel="bookmark"><time class="entry-date published updated" datetime="2021-12-09T09:35:11-05:00" itemprop="dateModified">Thursday, December 9, 2021</time><time class="updated" datetime="2021-12-07T14:26:55-05:00" itemprop="datePublished">Tuesday, December 7, 2021</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>There is a gap between the number of patients needed to participate in new cancer trials and the number who give consent to take part. Decentralized clinical trials (DCTs) are helping to address this gap by increasing the reach of clinical studies beyond conventional research sites. DCTs provide an opportunity … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-8596 --> <article id="post-7835" class="post-7835 post type-post status-publish format-standard has-post-thumbnail hentry category-commercialization category-decentralized-clinical-trials category-oncology category-phase-iib-iii tag-decentralized-clinical-trials-dct tag-decentralized-trials latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog-450x300.jpg" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="DCTBlog" srcset="https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog-450x300.jpg 450w, https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog-91x60.jpg 91w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="7836" data-permalink="https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/dctblog/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog.jpg" data-orig-size="618,407" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog-300x198.jpg" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2021/04/DCTBlog.jpg" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/&title=Decentralized%20Clinical%20Trials%20(DCT)%20Monthly%20Blog%20–%20March%202021" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Decentralized%20Clinical%20Trials%20(DCT)%20Monthly%20Blog%20–%20March%202021 https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#3d026e485f57585e490079585e5853494f5c5154475859180f0d7e515453545e5c51180f0d694f545c514e180f0d15797e6914180f0d70525349555144180f0d7f51525a180f0d1b1e050f0c0c06180f0d705c4f5e55180f0d0f0d0f0c1b1e0d0e05067f525944005549494d4e07121259595f51525a13515c5f5e524f4d135e5250120f0d0f0c120d0e1259585e5853494f5c5154475859105e515453545e5c5110494f545c514e12" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/" rel="bookmark">Decentralized Clinical Trials (DCT) Monthly Blog – March 2021</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2021/03/decentralized-clinical-trials/" rel="bookmark"><time class="entry-date published updated" datetime="2021-06-03T16:22:25-04:00" itemprop="dateModified">Thursday, June 3, 2021</time><time class="updated" datetime="2021-03-29T15:23:00-04:00" itemprop="datePublished">Monday, March 29, 2021</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>This month, we want to highlight the growing connections between decentralized clinical trials (DCTs) and the critical therapeutic area of oncology.</p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-7835 --> <article id="post-7756" class="post-7756 post type-post status-publish format-standard has-post-thumbnail hentry category-discovery category-drug-development category-oncology category-phase-i-iia tag-flow-cytometry latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-450x300.jpg" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="Greenfield3801" srcset="https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-450x300.jpg 450w, https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-300x200.jpg 300w, https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-1024x683.jpg 1024w, https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-768x512.jpg 768w, https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-90x60.jpg 90w, https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801.jpg 1500w" sizes="(max-width: 450px) 100vw, 450px" data-attachment-id="7760" data-permalink="https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/greenfield3801/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801.jpg" data-orig-size="1500,1000" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-300x200.jpg" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2021/03/Greenfield3801-1024x683.jpg" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/&title=Minimal%20Residual%20Disease%20by%20Flow%20Cytometry:%20Latest%20Insights%20on%20Validation" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Minimal%20Residual%20Disease%20by%20Flow%20Cytometry:%20Latest%20Insights%20on%20Validation https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#84bbd7f1e6eee1e7f0b9c9edeaede9e5e8a1b6b4d6e1f7ede0f1e5e8a1b6b4c0edf7e1e5f7e1a1b6b4e6fda1b6b4c2e8ebf3a1b6b4c7fdf0ebe9e1f0f6fdbea1b6b4c8e5f0e1f7f0a1b6b4cdeaf7ede3ecf0f7a1b6b4ebeaa1b6b4d2e5e8ede0e5f0edebeaa2a7b4b7bcbfc6ebe0fdb9ecf0f0f4f7beababe0e0e6e8ebe3aae8e5e6e7ebf6f4aae7ebe9abb6b4b6b5abb4b7abe9edeaede9e5e8a9f6e1f7ede0f1e5e8a9e0edf7e1e5f7e1a9e6fda9e2e8ebf3a9e7fdf0ebe9e1f0f6fda9e8e5f0e1f7f0a9edeaf7ede3ecf0f7a9ebeaa9f2e5e8ede0e5f0edebeaab" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/" rel="bookmark">Minimal Residual Disease by Flow Cytometry: Latest Insights on Validation</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2021/03/minimal-residual-disease-by-flow-cytometry-latest-insights-on-validation/" rel="bookmark"><time class="entry-date published updated" datetime="2021-06-08T16:46:46-04:00" itemprop="dateModified">Tuesday, June 8, 2021</time><time class="updated" datetime="2021-03-22T16:43:56-04:00" itemprop="datePublished">Monday, March 22, 2021</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-7756 --> <article id="post-7713" class="post-7713 post type-post status-publish format-standard has-post-thumbnail hentry category-drug-development category-oncology category-phase-i-iia category-phase-iib-iii latest_post" itemscope itemtype="https://schema.org/Blog"> <a href="https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/" class="post-thumbnail"><img width="450" height="300" src="https://ddblog.labcorp.com/wp-content/uploads/2021/01/1-29-2021-2-36-58-PM-1-450x300.jpg" class="attachment-blossom-feminine-cat size-blossom-feminine-cat wp-post-image" alt="MMM" data-attachment-id="7719" data-permalink="https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/1-29-2021-2-36-58-pm-2/" data-orig-file="https://ddblog.labcorp.com/wp-content/uploads/2021/01/1-29-2021-2-36-58-PM-1.jpg" data-orig-size="803,598" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="" data-image-description="" data-medium-file="https://ddblog.labcorp.com/wp-content/uploads/2021/01/1-29-2021-2-36-58-PM-1-300x223.jpg" data-large-file="https://ddblog.labcorp.com/wp-content/uploads/2021/01/1-29-2021-2-36-58-PM-1.jpg" /></a> <div class="text-holder"> <header class="entry-header"> <div class="top"> <div class="share"> <i class="fa fa-share-alt"></i>Share <div class="social-networks"> <ul> <li><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/&title=Innovation%20in%20Plasma%20Cell%20Enrichment%20for%20Multiple%20Myeloma%20Studies" rel="nofollow" target="_blank"><i class="fa fa-linkedin" aria-hidden="true"></i></a></li><li><a href="https://twitter.com/home?status=Innovation%20in%20Plasma%20Cell%20Enrichment%20for%20Multiple%20Myeloma%20Studies https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/" rel="nofollow" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a></li><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/" rel="nofollow" target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a></li><li><a href="/cdn-cgi/l/email-protection#49761a3c2b232c2a3d74002727263f283d2026276c7b7920276c7b791925283a24286c7b790a2c25256c7b790c273b202a21242c273d6c7b792f263b6c7b79043c253d2039252c6c7b7904302c252624286c7b791a3d3c2d202c3a6f6a797a71720b262d3074213d3d393a7366662d2d2b25262e6725282b2a263b39672a2624667b797b7866797b66202727263f283d202627642027643925283a2428642a2c2525642c273b202a21242c273d642f263b64243c253d2039252c6424302c25262428643a3d3c2d202c3a66" rel="nofollow" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a></li> </ul> </div> </div> </div><h2 class="entry-title" itemprop="headline"><a href="https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/" rel="bookmark">Innovation in Plasma Cell Enrichment for Multiple Myeloma Studies</a></h2><div class="entry-meta"><span class="byline" itemprop="author" itemscope itemtype="https://schema.org/Person"> by <span class="author vcard" itemprop="name"><a class="url fn n" href="https://ddblog.labcorp.com/author/covance/">Labcorp</a></span></span><span class="posted-on"><span class="text-on">updated on </span><a href="https://ddblog.labcorp.com/2021/02/innovation-in-plasma-cell-enrichment-for-multiple-myeloma-studies/" rel="bookmark"><time class="entry-date published updated" datetime="2021-06-03T17:49:26-04:00" itemprop="dateModified">Thursday, June 3, 2021</time><time class="updated" datetime="2021-02-08T07:00:00-05:00" itemprop="datePublished">Monday, February 8, 2021</time></a></span></div><!-- .entry-meta --> </header><!-- .entry-header home--> <div class="entry-content" itemprop="text"> <p>Syndecan-1 (SDC1), also known as CD138, is a well-known and specific plasma cell marker that is highly expressed on the surface of multiple myeloma plasma cells. As it can be a challenge detecting the small number of malignant plasma cells within the large proportion of cells obtained from a bone … </p> </div><!-- .entry-content --> <footer class="entry-footer"> </footer><!-- .entry-footer home--> </div><!-- .text-holder --> </article><!-- #post-7713 --> </div> <div class="pagination"></div> </main><!-- #main --> </div><!-- #primary --> </div><!-- .row/not-found --> </div><!-- #content --> </div><!-- .container/.main-content --> <footer id="colophon" class="site-footer" itemscope itemtype="http://schema.org/WPFooter"> <div class="site-info"> <div class="container"> <span class="copyright">Copyright © 2022 Labcorp All rights reserved.</span> </div> </div> </footer><!-- #colophon --> <button aria-label="go to top" id="blossom-top"> <span><i class="fa fa-angle-up"></i>TOP</span> </button> </div><!-- #page --> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/all.min.js?ver=5.6.3'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/v4-shims.min.js?ver=5.6.3'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/sticky-kit.min.js?ver=1.1.3'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/owl.carousel.min.js?ver=2.2.1'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/owl.carousel.aria.min.js?ver=2.0.0'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/jquery.matchHeight.min.js?ver=0.7.2'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/wow.min.js?ver=1.1.3'></script> <script type='text/javascript'> /* <![CDATA[ */ var bfp_data = {"lightbox":"","auto":"","loop":"","speed":"3000","animation":"fadeOut","child":"default","sticky":"","sticky_widget":"","header":"eight","url":"https:\/\/ddblog.labcorp.com\/wp-admin\/admin-ajax.php","rtl":""}; /* ]]> */ </script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/custom.min.js?ver=2.3.3'></script> <script type='text/javascript'> /* <![CDATA[ */ var bfp_ajax = {"url":"https:\/\/ddblog.labcorp.com\/wp-admin\/admin-ajax.php","startPage":"1","maxPages":"5","nextLink":"https:\/\/ddblog.labcorp.com\/therapeutic-area\/oncology\/page\/2\/","autoLoad":"load_more","loadmore":"Load More Posts","loading":"Loading...","nomore":"No More Post","layouts":"two-col-right","plugin_url":"https:\/\/ddblog.labcorp.com\/wp-content\/plugins"}; /* ]]> */ </script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-content/themes/blossom-feminine-pro/js/ajax.min.js?ver=2.3.3'></script> <script type='text/javascript' src='https://ddblog.labcorp.com/wp-includes/js/wp-embed.min.js?ver=5.4'></script> <script type="text/javascript"> if(typeof _satellite !== "undefined"){ _satellite.pageBottom(); } </script> <script defer src="https://static.cloudflareinsights.com/beacon.min.js/v8b253dfea2ab4077af8c6f58422dfbfd1689876627854" integrity="sha512-bjgnUKX4azu3dLTVtie9u6TKqgx29RBwfj3QXYt5EKfWM/9hPSAI/4qcV5NACjwAo8UtTeWefx6Zq5PHcMm7Tg==" data-cf-beacon='{"rayId":"80cdbd7fdfe6388c","version":"2023.8.0","b":1,"token":"82cf85107b3e414383a3287524210878","si":100}' crossorigin="anonymous"></script> </body> </html>